Jul 152013
 

File:Belinostat.svg

Belinostat

Melphalan

Apaziquone

 Raj Shrotriya, Spectrum’s chairman, president and CEO, likes to be an acquirer, analysts say. To boost the value of Spectrum’s stock, Shrotriya could enter into a merger agreement with a larger pharmaceutical company or acquire another drugmaker with an attractive product. He is confident that as a stand-alone company, Spectrum has the potential of becoming a larfger company with a bigger and diversified presence in the pharmaceutical industry.

Shrotriya says over the next 18 months, he expects Spectrum will be filing three new drug applications with the FDA — for Belinostat, a pan-HDAC inhibitor that could have the potential of becoming a backbone of chemotherapy along with carplatin and paclitaxel; Melphalan, a unique formulation used as a conditioning regimen for bone marrow transplant in certain diseases; and Apaziquone.

http://www.forbes.com/sites/genemarcial/2013/07/14/tiny-biotech-with-three-cancer-drugs-is-more-alluring-takeover-bet-now/

Share

 Leave a Reply

(required)

(required)


× 6 = twenty four

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: